Skip to main content

Zyomyx Nabs $10M in Series F Round; Mouse Protein Chip Due in April

NEW YORK, Feb. 12 (GenomeWeb News) - Protein biochip company Zyomyx has raised $10 million in a Series F round of private-equity financing, the company said today.


Zyomyx said it plans to use the cash to continue developing its protein chip technology. It expects to launch its Murine Cytokine Biochip in April 2004.

 

CSFB Private Equity led the round with existing investors Alloy Ventures, Lilly BioVentures, Hambrecht & Quist Capital Management, Mediphase Venture Partners, Bio*One Capital, and the Biomedical Sciences investment arm of the Singapore Economic Development Board.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.